Our results highlight the importance of ongoing efforts aimed at developing or improving new brain penetrant statin derivatives with improved efficacy and lessened negative effects [79], or DKK1 antagonists [57, 80] to promote or protect neurogenesis, neuronal connectivity and cognitive function in AD patients. Here, DKK1 is linked to Alzheimer disease.